Amicus Therapeutics (NASDAQ:FOLD) CEO Bradley Campbell Sells 14,587 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley Campbell sold 14,587 shares of Amicus Therapeutics stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $10.04, for a total value of $146,453.48. Following the sale, the chief executive officer owned 1,137,282 shares of the company’s stock, valued at approximately $11,418,311.28. This trade represents a 1.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock traded up $0.15 during mid-day trading on Thursday, hitting $10.02. 3,136,374 shares of the company traded hands, compared to its average volume of 4,236,660. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $10.57. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of -83.49 and a beta of 0.66. The stock has a fifty day moving average price of $8.73 and a 200-day moving average price of $7.34.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. The firm had revenue of $169.06 million for the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a negative net margin of 6.67% and a negative return on equity of 5.07%. The business’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter last year, the company posted $0.10 EPS. Amicus Therapeutics has set its FY 2025 guidance at EPS. On average, equities analysts predict that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on FOLD. The Goldman Sachs Group increased their price target on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Tuesday. JPMorgan Chase & Co. lifted their price objective on Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Needham & Company LLC upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.57.

Institutional Trading of Amicus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. purchased a new stake in Amicus Therapeutics during the 1st quarter valued at $1,533,000. Invesco Ltd. increased its holdings in Amicus Therapeutics by 4.1% in the 1st quarter. Invesco Ltd. now owns 2,661,394 shares of the biopharmaceutical company’s stock worth $21,717,000 after buying an additional 105,856 shares in the last quarter. Victory Capital Management Inc. raised its position in Amicus Therapeutics by 47.4% in the 1st quarter. Victory Capital Management Inc. now owns 257,088 shares of the biopharmaceutical company’s stock worth $2,098,000 after buying an additional 82,691 shares during the last quarter. Capital Fund Management S.A. grew its stake in shares of Amicus Therapeutics by 408.8% in the first quarter. Capital Fund Management S.A. now owns 312,561 shares of the biopharmaceutical company’s stock worth $2,550,000 after acquiring an additional 251,134 shares during the period. Finally, Jump Financial LLC raised its holdings in shares of Amicus Therapeutics by 101.8% during the first quarter. Jump Financial LLC now owns 406,168 shares of the biopharmaceutical company’s stock valued at $3,314,000 after purchasing an additional 204,941 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.